|
Pluristem to Present to President Bush and Others at the First Annual Israeli
Presidential Conference
Wednesday April 23, 10:53
am ET
|
|
|
NEW YORK--(BUSINESS WIRE)--Pluristem
Therapeutics Inc. (NASDAQ:PSTI
- News) (DAX:PJT),
a bio-therapeutics company dedicated to the
commercialization of non-personalized (allogeneic) cell
therapy products for a variety of degenerative, ischemic and
autoimmune indications, announced today that it has been
chosen to present at the First Annual Israeli Presidential
Conference termed “Facing
Tomorrow", to be held on May 13-15, 2008 in Jerusalem.
The conference will focus on Jewish and
Israeli contributions to humanity and will showcase 60 (for
the 60th anniversary of the State of
Israel), meticulously selected out of hundreds,
inventions and innovations developed by Israeli scientists,
researchers and inventors, that have the potential to
revolutionize the future for Israel and the world community
alike.
World leaders, artists, scientists and
entrepreneurs will take part in the event. Confirmed
conference participants include President George W. Bush,
Former British Prime Minister Tony Blair; Former President
of the USSR Mikhail Gorbachev; Former US Secretary of State
Dr. Henry Kissinger; New York Times columnist Thomas L.
Friedman;
Chairman and
CEO
of
News Corporation Rupert Murdoch; and Harvard Law
Professor Alan Dershowitz.
Zami Aberman, Pluristem’s
President & CEO, stated: “Pluristem
is pleased to be invited to this high level international
conference to present its business and products in
development to world-renowned business leaders, technology
thought leaders and entrepreneurs.”
About Pluristem
Pluristem Therapeutics Inc. is a
bio-therapeutics company dedicated to the commercialization
of non-personalized (allogeneic) cell therapy products for
the treatment of a number of severe degenerative, ischemic
and autoimmune disorders. The Company is developing a
pipeline of products, stored ready-to-use, that are derived
from the human placenta, a non-controversial, non-embryonic,
adult stem cell source.
These placental mesenchymal stromal cells (MSCs)
are expanded in the Company’s
proprietary PluriX™ 3D bioreactor,
which imitates the natural microstructure of bone marrow and
does not require supplemental growth factors or other
exogenous materials. Pluristem believes the resultant PLX (PLacental
eXpanded) cells are multi-potent and able to differentiate
into a variety of cell types. Recent evidence also suggests
their efficacy may be related to the secretion of cytokines
or other potent immune modulators. Furthermore, PLX cells
are immune privileged and have immunomodulatory properties,
thus protecting the recipient from immunological reactions
that often accompany transplantations.
Pluristem’s first
product in development, PLX-PAD, is intended to improve the
quality of life of millions of people suffering from
peripheral artery disease (PAD). The Company’s
products in development also include the PLX-BMT, targeting
the global shortfall of matched tissue for bone marrow
transplantation (BMT) by improving the engraftment of
hematopoietic stem cells (HSCs) contained in umbilical cord
blood; the PLX-STROKE, targeting ischemic stroke; and the
PLX–MS, targeting Multiple
Sclerosis.
Pluristem has offices in the USA, with
headquarters housing its R&D and GMP-approved manufacturing
facilities in Haifa, Israel.
See our product animation on YouTube:
http://www.youtube.com/watch?v=OFhWXyJT6Us.
Safe Harbor Statement
This press release contains forward-looking
statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. These forward-looking
statements are based on the current expectations of the
management of Pluristem only, and are subject to a number of
factors and uncertainties that could cause actual results to
differ materially from those described in the
forward-looking statements. The following factors, among
others, could cause actual results to differ materially from
those described in the forward-looking statements: changes
in technology and market requirements; our technology may
not be validated as we progress further and our methods may
not be accepted by the scientific community; we may be
unable to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen
scientific difficulties may develop with our process;
results in the laboratory may not translate to equally good
results in real surgical settings; our patents may not be
sufficient; our products may harm recipients; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; loss of market
share and pressure on pricing resulting from competition,
which could cause the actual results or performance of
Pluristem to differ materially from those contemplated in
such forward-looking statements. Except as otherwise
required by law, Pluristem undertakes no obligation to
publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risk and
uncertainties affecting Pluristem, reference is made to
Pluristem's reports filed from time to time with the
Securities and Exchange Commission.
For more information visit our website at
www.pluristem.com,
the content of which is not part of this press release.
Contact:
Pluristem Therapeutics Inc.
William Prather RPh, MD
Sr. VP Corporate Development
303-883-4954
bill@pluristem.com
Source:
Pluristem Therapeutics Inc.
|
|
|
|
